

## **ORIGIO a/s establish a joint venture with focus on sales of IVF equipment**

Jyllinge, Denmark, June 21, 2010, ORIGIO a/s (OSE: ORO), a leader in Assisted Reproductive Technologies (ART), has today signed a Shareholders Agreement with LaboGene ApS with the intent to establish a joint venture specializing in sales of equipment for IVF laboratories worldwide.

The new company, called ORIGIO ScanLab Equipment a/s, will be owned 51 per cent by ORIGIO a/s and 49 per cent by LaboGene ApS. The joint venture will be operational from July 1, 2010.

LaboGene ApS is a Danish company that specializes in the design, development and manufacture of laboratory and industrial equipments in the fields of Clean Air & Laminar Flow, Vacuum & Cooling and Centrifugation. LaboGene has been the ORIGIO MidAtlantic Devices supplier of laminar flow cabinets to the Americas IVF market for many years.

"We already offer selected pieces of world-class equipment for IVF labs but with the creation of this joint venture we substantially expand our product range of high quality IVF equipments. This emphasizes our long term commitment to supplying a specialized portfolio of the very best products for the IVF industry and thereby to continuously service their requirements more fully." says Jesper Funding Andersen, CEO of ORIGIO a/s.

"The creation of ORIGIO ScanLab Equipment a/s is important to us as we acquire access to ORIGIO sales teams and to an extensive network of distribution partners. The joint venture is therefore a perfect match as we want to offer the best available IVF equipment for this important market sector. LaboGene have already established a wide experience and expertise in on-site installations and after sales service." says Mr. Finn Kokholm, CEO of LaboGene ApS.

Finn Kokholm, will be the CEO of ORIGIO ScanLab Equipment and Jamie Bennett will be the Technical Sales Director of the JV. ORIGIO ScanLab Equipment will source services from both ORIGIO a/s and LaboGene ApS. The company will be located in Lyngø, Denmark.

The creation of the joint venture is expected to have an insignificant impact on ORIGIO's financials for 2010, but already to add positively to ORIGIO's EBITDA and operating cash flow from 2011 and onwards.

*For further information, please contact:*

*Jesper Funding Andersen, CEO ORIGIO a/s: +45 4073 0963 or E-mail: [jfandersen@origio.com](mailto:jfandersen@origio.com)*

*Jakob Brix Christensen, Director Investor Relations: +45 2144 4811 or E-mail: [jbrix@origio.com](mailto:jbrix@origio.com)*

*Finn Kokholm, CEO LaboGene ApS: +45 3016 0990 or E-mail: [fk@labogene.com](mailto:fk@labogene.com)*

### **About ORIGIO a/s**

*ORIGIO a/s is a world leader in Assisted Reproductive Technology (ART) solutions. Through research and innovation, ORIGIO aims to provide the best products to medical professionals to assist the #1 dream of every infertile couple to come true. ORIGIO currently comprises of the three product families MediCult Media, Humagen Pipets and MidAtlantic Devices, that caters for the broadest range of ART requirements. ORIGIO, whose headquarters are in Jyllinge, Denmark and have companies in nine countries, is listed on the Oslo Stock Exchange (ORO). For further information, please visit [www.origio.com](http://www.origio.com).*

### **About LaboGene ApS**

*LaboGene ApS is a world leader in the design and manufacture of Class 2 microbiological safety cabinets, laminar flow work stations and centrifuges, freeze dryers, vacuum concentrators, ultra low freezers and enclosures for IVF. LaboGene are recognised as the leading innovators of energy saving concepts and operator comfort ergonomic designs in their construction. Since the early 1990's the people of LaboGene have established a reputation of quality, reliability and after care service for their products which are sold world wide by a selected team of factory trained dealers, distributors and accredited service teams.*

**Forward Looking Statements**

*Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. There can be no assurance that any of the forward-looking statements identified in this press release will occur. Conducting studies for investigational products are subject to risks and uncertainties. There can be no assurance that planned studies can be initiated, that planned or ongoing studies can be successfully concluded or concluded in accordance with ORIGIO's anticipated schedule. These factors, and other factors, including, but not limited to those described in ORIGIO's most recent annual report, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ORIGIO does not assume any responsibility for updating any forward-looking statements.*